Last reviewed · How we verify

NCT02031120: DHC

Management of Drug Hypersensitivity in Children

Terminated Last updated 19 March 2025
What this trial tests

trial in Drug Hypersensitivity in 207 participants. Terminated before completion.

Timeline
21 May 2014
Primary endpoint
28 February 2019
28 February 2019

Quick facts

Lead sponsorUniversity Hospital, Geneva
StatusTerminated
Study typeOBSERVATIONAL
Enrollment207
Start date21 May 2014
Primary completion28 February 2019
Estimated completion28 February 2019
Sites1 location across Switzerland

Conditions studied

Sponsor

University Hospital, Geneva

Who can join

Under 16, any sex, with Drug Hypersensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is (1) to assess the incidence of suspected drug allergies in a pediatric hospital and the proportion in which these reactions are confirmed to be allergic; (2) to evaluate the diagnostic values of the different allergy tests available; (3) to investigate the pathophysiology of drug allergies, particularly by investigating the role of viruses, and by performing HLA typing and a gene expression profile both in the acute phase of the reaction and 2 months later.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Drug Hypersensitivity

Currently open trials in the same condition.

Other University Hospital, Geneva trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02031120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing